Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4807)
All Articles published online
|
Jul 7, 2010 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol 2010; 16(25): 3187-3195 [PMID: 20593505 DOI: 10.3748/wjg.v16.i25.3187] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i25/3187.htm |
| Number | Citing Articles |
| 1 |
L. Beaugerie. Commentary: monitoring for myelosuppression in IBD. Alimentary Pharmacology & Therapeutics 2013; 37(1): 154 doi: 10.1111/apt.12108
|
| 2 |
Mahmoud H Mosli, William J Sandborn, Richard B Kim, Reena Khanna, Bandar Al-Judaibi, Brian G Feagan. Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. American Journal of Gastroenterology 2014; 109(7): 994 doi: 10.1038/ajg.2014.110
|
| 3 |
Richard Myles Turner, Munir Pirmohamed. Preventive and Predictive Genetics: Towards Personalised Medicine. Advances in Predictive, Preventive and Personalised Medicine 2015; 9: 109 doi: 10.1007/978-3-319-15344-5_6
|
| 4 |
Geoffrey C. Wall, Hamid Muktar, Cassandra Effken, Pramod B. Mahajan. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2018; 38(2): 259 doi: 10.1002/phar.2067
|
| 5 |
Simran D. S. Maggo, Ruth L. Savage, Martin A. Kennedy. Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. Clinical Pharmacokinetics 2016; 55(4): 419 doi: 10.1007/s40262-015-0324-9
|
| 6 |
Marta Gutiérrez-Valencia, Leire Leache, Luis Carlos Saiz, Juan J. Beloqui, Miguel Barajas, Miren Vicuña, Juan Erviti. Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 2023; 57(7): 671 doi: 10.1097/MCG.0000000000001791
|
| 7 |
Vishakha Tambe, Bhagwat Sirsat, Kuldeep Rajpoot, Anuradha Gadeval, Rakesh Kumar Tekade. Biopharmaceutics and Pharmacokinetics Considerations. 2021; : 355 doi: 10.1016/B978-0-12-814425-1.00021-8
|
| 8 |
Choon Jin Ooi, Govind K Makharia, Ida Hilmi, Peter R Gibson, Kwong Ming Fock, Vineet Ahuja, Khoon Lin Ling, Wee Chian Lim, Kelvin T Thia, Shu‐chen Wei, Wai Keung Leung, Poh Koon Koh, Richard B Gearry, Khean Lee Goh, Qin Ouyang, Jose Sollano, Sathaporn Manatsathit, H Janaka de Silva, Rungsun Rerknimitr, Pises Pisespongsa, Muhamad Radzi Abu Hassan, Joseph Sung, Toshifumi Hibi, Christopher C M Boey, Neil Moran, Rupert W L Leong. Asia–Pacific consensus statements on Crohn's disease. Part 2: Management. Journal of Gastroenterology and Hepatology 2016; 31(1): 56 doi: 10.1111/jgh.12958
|
| 9 |
Marieke J.H. Coenen, Dirk J. de Jong, Corine J. van Marrewijk, Luc J.J. Derijks, Sita H. Vermeulen, Dennis R. Wong, Olaf H. Klungel, Andre L.M. Verbeek, Piet M. Hooymans, Wilbert H.M. Peters, Rene H.M. te Morsche, William G. Newman, Hans Scheffer, Henk-Jan Guchelaar, Barbara Franke, A.A.M. Masclee, M. Pierik, W. Mares, W. Hameeteman, P.J. Wahab, H. Seinen, M.C.M. Rijk, I.M. Harkema, M. de Bièvre, L. Oostenbrug, C.M. Bakker, M. Aquarius, C. van Deursen, A.B. van Nunen, J.G. Goedhard, M. Hamacher, I.A.M. Gisbertz, B.J. Brenninkmeijer, A.C.I.T.L. Tan, M.N. Aparicio-Pagés, E.M. Witteman, S.A.C. van Tuyl, R. Breumelhof, A. Stronkhorst, L.P.L. Gilissen, E.J. Schoon, J.W.M. Tjhie-Wensing, A. Temmerman, J.J. Nicolaï, J.D. van Bergeijk, D.J. Bac, B.J.M. Witteman, N. Mahmmod, J.J. Uil, H. Akol, R.J.T. Ouwendijk, I.P. van Munster, M. Pennings, A.M.P. De Schryver, T.J.M. van Ditzhuijsen, R.C.H. Scheffer, T.E.H. Römkens, D.L. Schipper, P.J. Bus, J.W.A. Straathof, M.L. Verhulst, P.J. Boekema, J.T. Kamphuis, H.J. van Wijk, J.M.J.L. Salemans, J.R. Vermeijden, S.D.J. van der Werf, R.J. Verburg, P. Spoelstra, J.M.L. de Vree, K. van der Linde, H.J.A. Jebbink, M. Jansen, H. Holwerda, N. van Bentem, J.J. Kolkman, M.G.V.M. Russel, G.H. van Olffen, M.J. Kerbert-Dreteler, M. Bargeman, J.M. Götz, R. Schröder, J.M. Jansen, L.P. Bos, L.G.J.B. Engels, M.J.L. Romberg-Camps, E.T.P. Keulen, A.A.J. van Esch, J.P.H. Drenth, M.C.A. van Kouwen, G.J.A. Wanten, T.J. Bisseling, T.E.H. Römkens, M.W.J. van Vugt, P.C. van de Meeberg, S.J. van den Hazel, W.N.H.M. Stuifbergen, M.J.A.L. Grubben, U. de Wit, G.A.H. Dodemont, R.F. Eichhorn, J.M.H. van den Brande, A. H.J. Naber, E.J. van Soest, P.J. Kingma, N.C. Talstra, K.F. Bruin, F.H.J. Wolfhagen, D.W. Hommes, P.P.J. van der Veek, J.C.A. Hardwick, R.J. Stuyt, H.H. Fidder, B. Oldenburg, T.G. Tan. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology 2015; 149(4): 907 doi: 10.1053/j.gastro.2015.06.002
|
| 10 |
G. V. Volynets, A. I. Khavkin. Inflammatory bowel disease and drug-induced liver damage. Experimental and Clinical Gastroenterology 2021; (10): 138 doi: 10.31146/1682-8658-ecg-194-10-138-146
|
| 11 |
Maria Cappello, Gaetano Cristian Morreale. The Role of Laboratory Tests in Crohn's Disease. Clinical Medicine Insights: Gastroenterology 2016; 9: CGast.S38203 doi: 10.4137/CGast.S38203
|
| 12 |
Paria Pashazadeh, Abdoljalal Marjani, Jahanbakhash Asadi, Masoud Khoshnia. Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease. Endocrine, Metabolic & Immune Disorders - Drug Targets 2019; 19(4): 541 doi: 10.2174/1871530318666181119153522
|
| 13 |
Ji Young Chang, Jae Hee Cheon. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. Digestive Diseases and Sciences 2019; 64(9): 2395 doi: 10.1007/s10620-019-05720-5
|
| 14 |
Vid Mlakar, Patricia Huezo-Diaz Curtis, Chakradhara Satyanarayana Uppugunduri, Maja Krajinovic, Marc Ansari. Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use. International Journal of Molecular Sciences 2016; 17(9): 1502 doi: 10.3390/ijms17091502
|
| 15 |
Patricia Zerra, John Bergsagel, Frank G. Keller, Glen Lew, Melinda Pauly. Maintenance Treatment With Low‐Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine‐Induced Pancreatitis. Pediatric Blood & Cancer 2016; 63(4): 712 doi: 10.1002/pbc.25841
|
| 16 |
Xando Díaz-Villamarín, Emilio Fernández-Varón, Michelle Carolina Rojas Romero, José Luis Callejas-Rubio, José Cabeza-Barrera, Alba Rodríguez-Nogales, Julio Gálvez, Rocío Morón. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation. Biomedicine & Pharmacotherapy 2023; 168: 115706 doi: 10.1016/j.biopha.2023.115706
|
| 17 |
Tiziana Larussa, Evelina Suraci, Margherita Lentini, Immacolata Nazionale, Luigia Gallo, Ludovico Abenavoli, Maria Imeneo, Francesco Saverio Costanzo, Giovanni Cuda, Francesco Luzza. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease. European Journal of Internal Medicine 2012; 23(3): 273 doi: 10.1016/j.ejim.2011.12.002
|
| 18 |
Christian Mottet, Alain M. Schoepfer, Pascal Juillerat, Jacques Cosnes, Florian Froehlich, Vera Kessler-Brondolo, Frank Seibold, Gerhard Rogler, Stephan R. Vavricka, Pierre Michetti. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2016; 22(11): 2733 doi: 10.1097/MIB.0000000000000923
|
| 19 |
Lie Li, Natalya Atkinson, Kristine R. Crews, Alejandro R. Molinelli. Clinical Applications of Mass Spectrometry in Drug Analysis. Methods in Molecular Biology 2024; 2737: 443 doi: 10.1007/978-1-0716-3541-4_41
|
| 20 |
Yago González-Lama, Javier P Gisbert. Monitoring thiopurine metabolites in inflammatory bowel disease. Frontline Gastroenterology 2016; 7(4): 301 doi: 10.1136/flgastro-2015-100681
|
| 21 |
Adriane D.M. Vorselaars, Johanna P. Cremers, Jan C. Grutters, Marjolein Drent. Cytotoxic agents in sarcoidosis. Current Opinion in Pulmonary Medicine 2014; 20(5): 479 doi: 10.1097/MCP.0000000000000078
|
| 22 |
Olof Modén, Bengt Mannervik. Redox and Cancer Part A. Advances in Cancer Research 2014; 122: 199 doi: 10.1016/B978-0-12-420117-0.00006-2
|
| 23 |
Giuseppe Novelli, Michela Biancolella. Encyclopedia of Life Sciences. 2011; doi: 10.1002/9780470015902.a0002012.pub2
|
| 24 |
Jaimin Amin, Brian Huang, Jessica Yoon, David Q. Shih. Update 2014. Inflammatory Bowel Diseases 2015; 21(2): 445 doi: 10.1097/MIB.0000000000000197
|
| 25 |
Hilbert S. de Vries, Rene H.M. te Morsche, Kevin Jenniskens, Wilbert H.M. Peters, Dirk J. de Jong. A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's disease. Journal of Crohn's and Colitis 2012; 6(5): 597 doi: 10.1016/j.crohns.2011.11.010
|
| 26 |
Birendra P. Sah, Shraddha Goyal, Michael C. Iannuzzi. Novel pharmacotherapy of sarcoidosis. Pharmacology & Therapeutics 2016; 157: 1 doi: 10.1016/j.pharmthera.2015.10.001
|
| 27 |
Ben Warner, Emma Johnston, Monica Arenas-Hernandez, Anthony Marinaki, Peter Irving, Jeremy Sanderson. A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterology 2018; 9(1): 10 doi: 10.1136/flgastro-2016-100738
|
| 28 |
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Current Gastroenterology Reports 2020; 22(9) doi: 10.1007/s11894-020-00781-3
|
| 29 |
Arvind I. Srinath, Neera Gupta, Sohail Z. Husain. Probing the Association of Pancreatitis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2016; 22(2): 465 doi: 10.1097/MIB.0000000000000611
|
| 30 |
Nathalie K. Zgheib, Thalia Arawi, Rami A. Mahfouz, Ramzi Sabra. Attitudes of Health Care Professionals Toward Pharmacogenetic Testing. Molecular Diagnosis & Therapy 2011; 15(2): 115 doi: 10.1007/BF03256401
|
| 31 |
Jasmine A Luzum, Jason C Cheung. Does Cardiology Hold Pharmacogenetics to an Inconsistent Standard? A Comparison of Evidence Among Recommendations. Pharmacogenomics 2018; 19(15): 1203 doi: 10.2217/pgs-2018-0097
|
| 32 |
Raphael P. Luber, Sailish Honap, Georgina Cunningham, Peter M. Irving. Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?. Frontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00279
|
| 33 |
Amine Benmassaoud, Xuanqian Xie, Motaz AlYafi, Yves Theoret, Alain Bitton, Waqqas Afif, Talat Bessissow. Thiopurines in the Management of Crohn’s Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study. Canadian Journal of Gastroenterology and Hepatology 2016; 2016: 1 doi: 10.1155/2016/1034834
|
| 34 |
Yue-Ping Liu, Hai-Yan Wu, Xiang Yang, Han-Qing Xu, Yong-Chuan Li, Da-Chuan Shi, Jun-Fu Huang, Qing Huang, Wei-Ling Fu, Yi-Hsiang Hsu. Association between Thiopurine S-methyltransferase Polymorphisms and Thiopurine-Induced Adverse Drug Reactions in Patients with Inflammatory Bowel Disease: A Meta-Analysis. PLOS ONE 2015; 10(3): e0121745 doi: 10.1371/journal.pone.0121745
|
| 35 |
Adriane D.M. Vorselaars, Wim A. Wuyts, Veronique M.M. Vorselaars, Pieter Zanen, Vera H.M. Deneer, Marcel Veltkamp, Michiel Thomeer, Coline H.M. van Moorsel, Jan C. Grutters. Methotrexate vs Azathioprine in Second-line Therapy of Sarcoidosis. Chest 2013; 144(3): 805 doi: 10.1378/chest.12-1728
|
| 36 |
Arno C. Hessels, Abraham Rutgers, Jan Stephan F. Sanders, Coen A. Stegeman, Marieke J. H. Coenen. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study. PLOS ONE 2018; 13(4): e0195524 doi: 10.1371/journal.pone.0195524
|
| 37 |
|
| 38 |
Gerhard Rogler, Luc Biedermann. Clinical Utility of Biomarkers in IBD. Current Gastroenterology Reports 2015; 17(7) doi: 10.1007/s11894-015-0449-x
|
| 39 |
Heh-Shiang Sheu, Yi-Ming Chen, Yi-Ju Liao, Chia-Yi Wei, Jun-Peng Chen, Hsueh-Ju Lin, Wei-Ting Hung, Wen-Nan Huang, Yi-Hsing Chen. Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune Diseases. Journal of Personalized Medicine 2022; 12(9): 1399 doi: 10.3390/jpm12091399
|
| 40 |
Yue-Ping Liu, Han-Qing Xu, Ming Li, Xiang Yang, Shu Yu, Wei-Ling Fu, Qing Huang, Margaret M DeAngelis. Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis. PLOS ONE 2015; 10(12): e0144234 doi: 10.1371/journal.pone.0144234
|
| 41 |
Paulina Núñez F, Rodrigo Quera, Constanza Bay, Fabiola Castro, Gabriel Mezzano. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2022; 16(7): 1168 doi: 10.1093/ecco-jcc/jjac013
|
| 42 |
Rohan V Yewale, Balakrishnan S Ramakrishna, Babu Vinish Doraisamy, Pandurangan Basumani, Jayanthi Venkataraman, Kayalvizhi Jayaraman, Ananthavadivelu Murali, Karunakaran Premkumar, Akkim Sathish Kumar. Long‐term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real‐world experience. JGH Open 2023; 7(9): 599 doi: 10.1002/jgh3.12955
|
| 43 |
Maria Shipkova, Jutta Franz, Manabu Abe, Corinne Klett, Eberhard Wieland, Tilo Andus. Association Between Adverse Effects Under Azathioprine Therapy and Inosine Triphosphate Pyrophosphatase Activity in Patients With Chronic Inflammatory Bowel Disease. Therapeutic Drug Monitoring 2011; 33(3): 321 doi: 10.1097/FTD.0b013e31821a7c34
|
| 44 |
Giuseppe Losurdo, Irene Vita Brescia, Chiara Lillo, Martino Mezzapesa, Michele Barone, Mariabeatrice Principi, Enzo Ierardi, Alfredo Di Leo, Maria Rendina. Liver involvement in inflammatory bowel disease: What should the clinician know?. World Journal of Hepatology 2021; 13(11): 1534-1551 doi: 10.4254/wjh.v13.i11.1534
|